There are 2 vaccines available for use within Australia to prevent the development of herpes zoster (shingles).

Zostavax is a live-attenuated vaccine and is funded on the National Immunisation Program (NIP) for immunocompetent adults aged 70 years and over.

Shingrix is a non-live vaccine. It is the preferred vaccine for those aged over 50 years due to a higher efficacy. It is currently only available for private purchase and availability is limited.

ATAGI have released a statement informing the use both vaccines. To read the statement in full please follow the link below:

ATAGI: Statement on the clinical use of zoster vaccines in older adults in Australia

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个